Trials / Withdrawn
WithdrawnNCT05146154
Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Illinois at Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imipenem/Cilastatin/Relebactam 1.25g | Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug. |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2023-06-01
- Completion
- 2024-01-01
- First posted
- 2021-12-06
- Last updated
- 2024-11-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05146154. Inclusion in this directory is not an endorsement.